Ischemic Conditioning Therapy: A New Path for Treatment of Endothelial Dysfunction and CVD ***Webinar ***Slides: Robert Kloner, M.D., Ph.D. ***Slides: Morteza Naghavi, M.D.

Ischemic Conditioning Therapy:
A New Path for Treatment of Endothelial Dysfunction and CVD

Dr. Robert Kloner a world renowned physician scientist who pioneered remote ischemic conditioning , and Dr. Morteza Naghavi the innovator of DTM endothelial function testing and personalized ischemic conditioning will discuss new promising avenues for treating endothelial dysfunction and cardiovascular diseases using Ischemic Conditioning. This Webinar intends to provide an update on a similar scientific events held jointly by Endothelix Inc. and IC Therapeutics Inc. in prior years available on www.endothelix.com and www.ictherapeutics.com 


 

Webinar Date: Today (Thursday, December 8, 2016)
Event Time:
2:00 – 3:00 PM PST
click here to register

Presentors:

   Dr-Kloner.jpg
Morteza Naghavi, M.D.
Dr. Naghavi is the founder and president of MEDITEX, a medical technology innovation and investment company dedicated to translating innovative ideas to healthcare solutions. He is also the Founder and Executive Chairman of the Society for Heart Attack Prevention and Eradication (SHAPE) based in Houston, Texas. Dr. Naghavi received his MD from Tehran University of Medical Sciences and was trained at the University of Texas Health Science Center in Houston and Texas Heart Institute where he served as a cardiology faculty member and Co-Director of the Vulnerable Plaque Research Department. Dr. Naghavi led advancing the field of “Vulnerable Plaque” to “Vulnerable Patient” and organized the SHAPE Task Force to focus on early detection and treatment of asymptomatic patients with subclinical atherosclerosis through the SHAPE Guidelines. He has over 30 inventions in the fields of interventional cardiology, noninvasive imaging, ambulatory diagnostics, wearable sensors, and personalized preventive healthcare. Among his inventions are digital thermal monitoring of vascular function and personalized ischemic conditioning device. Dr. Naghavi has numerous publications and is the editor of Asymptomatic Atherosclerosis; Pathophysiology,Detection and Treatment.

Robert A. Kloner, M.D., Ph.D.

Dr. Kloner is the Director of Cardiovascular Research Institute and Vice President of Translation at the Huntington Medical Research Institutes in Pasadena, CA. and Professor of Clinical Medicine at the Keck School of Medicine at University of Southern California in Los Angeles. Dr. Kloner received his MD and PhD degrees from Northwestern University Medical School in Chicago and clinical and research fellowships in medicine and cardiology at Harvard Medical School and Brigham and Women’s Hospital where he served as Assistant and then Associate Professor. Among Dr. Kloner’s major research interests are protection of ischemic myocardium, development of therapies for limiting myocardial infarct size. He has participated in studies funded by the National Institutes of Health on cardiac cell transplantation, doxorubicin cardiomyopathy, functional analysis of cardiac grafts, and stem cells. Dr.Kloner has contributed over 683 original papers in peer-reviewed journals; over 217 chapters or monographs and over 497 abstracts. Dr. Kloner is the author and editor of 18 medical texts including: Ischemic Preconditioning, Cardiovascular Trials Reviews (10 editions), and The Guide to Cardiology (3 editions). Dr. Kloner is known as the pioneer in the field of remote ischemic conditioning.

 

click here to register
*This educational event is sponsored by: Endothelix Inc. and Ischemic Conditioning Therapeutics, Inc.
View presentations from prior events at: www.endothelix.com and www.ictherapeutics.com

Leave a Reply

LATEST SCIENTIFIC UPDATES

Enhance your patient care with the new office-based vascular function test.

Sign Up for our Webinar Series

Why Should We Measure Endothelial Function?